Theme: Understanding the Flu and Infectious Diseases; Risk Analysis and Prevention

Flu-2017

Flu-2017

About Conference

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Flu 2016, Conference Series LLC is delighted to announce the next event

Conference Series invites all the participants from all over the world to attend 3rd International Conference on Flu & Emerging Infectious Diseases during October 30-November 01, 2017 at Las Vegas, USA.

The field of Flu & Emerging Infectious Diseases is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

World Flu & Emerging Infectious Diseases 2017

 Opportunity to attend the presentations delivered by eminent scientists from all over the world. Selected contributions will be published in following Conference Series Journals             

·         Virology & Mycology

·         Virology & Antiviral Research

·         Journal of Vaccines & Vaccination

Participation in sessions on specific topics on which the conference is expected to achieve progress

Global networking: In transferring and exchanging Ideas

Conference brings together Scientific Researchers, Virologists, Immunologists, Microbiologists, Pathologists, Infectious Diseases Specialists, Health Care Professionals and Physicians





Sessions/Tracks

Track 1: Emerging Infectious Diseases

An infectious disease whose occurrence has increased in the past years or threatens to increase is termed as emerging. These diseases include new infections, previously unrecognized infections and old infections reappearing due to antimicrobial resistance and public health issues due to unhygienic conditions. Many emerging diseases are zoonotic - an animal reservoir incubates the organism, with only occasional transmission into human populations.. Emerging Infectious Disease are caused by newly identified strains like SARS, AIDS that may have evolved from a known infection like influenza or spread to a new population  or strain for e.g. West Nile virus or area undergoing ecologic transformation like Lyme disease or be re-emerging infections like drug resistant tuberculosis. Of growing concern are adverse synergistic interactions between emerging diseases and other infectious and non - infectious conditions leading to the development of novel syndemics.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 2: Characteristics and Transmission of Emerging Infectious Disease

An Emerging Infectious disease whose occurrence has expanded in the past years or threatens to increase is called emerging infectious diseases. These diseases incorporate new infections or diseases, previously unrecognized infections and old infections reappearing due to antimicrobial/antiviral resistance, public health issues and unhygienic conditions. Emerging Infectious disease can be transmitted from person to person by direct or indirect contact. Microorganisms, viruses, parasites, and fungi are common source of transmission. Mechanism of Microbial resistance by microorganisms includes mechanisms of enzymatic modification, enzymatic destruction, altered target and decreased uptake. Resistance mechanism works due to the inactivation or modification of antibiotics, an alteration in the target site of the antibiotic that reduces its binding capacity, the modification of metabolic pathways to circumvent the antibiotic effect and the reduced intracellular antibiotic accumulation by decreasing permeability and/ or increasing active efflux of the antibiotic.

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 3: Therapeutic Studies and Approaches including Immunization

The framework is additionally a convoluted arrangement of cooperation of cells to segregate antigens, subsequently shielding the living beings from contaminations of assorted classes. Vaccination is considered to be one in everything about conservative procedures in bar of innumerable sicknesses; insusceptibility that is given due to vaccination is agile for wipeout of the different contaminations and illnesses though debilitating the consequences of the numerous different infections especially inside the creating nations. There are those vaccination, that are regulated completely when the patient has gotten an ailment. The intent of such vaccination is to trigger a rapid response with debilitated symptoms and hurt as that of the regular contamination. Recognizable proof of a particular specialist for a specific contamination or a wellbeing issue is done in clinical presentation. Diagnostic biological science laboratory plays a vital role in diagnosing with uninflected of microbiological culture being the primitive approach for isolation of the favorable living being inside the lab that is that then nearly taken after by the natural science tests then propelled therapeutic science measures and in this manner a definitive stride is the compound responses.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 4: Understanding Diseases Risks and Control

Infectious diseases prevention and control is helpful to prevent the transmission of infectious diseases. Aseptic technique is normally applied to prevent the infections caused by different means. Sterilization is another process of killing microorganisms by the application of heat. Disinfection is the process of killing harmful microorganisms. Some infectious diseases can be prevented by avoiding direct contact with the contagious person. Infections can also be controlled and prevented by creating public awareness on various infectious diseases and their outbreaks. Infections can be cured by various antimicrobials.

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 5: Flu Vaccines: Current and Novel Approach

Flu Vaccine is an annual vaccination using a vaccine that is specific for a given year to protect against the highly variable influenza virus. Risk management and effectiveness of vaccines are important for public health. In the United States, NIAID laboratories are developing novel vaccine candidates for seasonal influenza viruses and for avian strains with pandemic potential. In late 2006, the NIAID Vaccine Research Center initiated the first human trial of an investigational DNA vaccine against the H5N1 avian influenza virus, a strain that has infected and continues to threaten humans. In addition, researchers in the NIAID Laboratory of Infectious Diseases are working with MedImmune to generate candidate live-attenuated vaccines for a broad range of influenza subtypes with pandemic potential. To date, five of these vaccine candidates have advanced to Phase I clinical trials. Many Ebola vaccine candidates had been developed in the decade prior to 2014, but none has yet been approved for clinical use in humans.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 6: Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups

These days success and challenges of vaccines on infants, children, pregnant women and elderly patient is major concern for influenza research. Evidence-based guidelines for immunization of infants, children, adolescents, and adults have been prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). These guidelines are prepared for health care professionals who care for either immunocompetent or immunocompromised people of all ages. Vaccine innovation and human health researchers try to determine how well flu vaccines work to regularly assess and confirm the value of flu vaccination as a public health intervention in each season. Study results about how well a flu vaccine works can vary based on study design, outcome(s) measured, population studied and the season in which the flu vaccine was studied. These differences can make it difficult to compare one study’s results with another’s. rough the support of the U.S. Department of Health and Human Services and NIAID, researchers are developing various influenza vaccine delivery technologies that will help the United States and the world be better prepared to mount a speedy response to the next pandemic

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 7: Pathology of Influenza Virus Infections

Influenza viruses are significant human respiratory pathogens that cause both seasonal, endemic infections and periodic, unpredictable pandemics. The pathologic changes described in the 1918 influenza pandemic is not significantly different from the histopathology observed in other less lethal pandemics or even in deaths occurring during seasonal influenza outbreaks. People with chronic pulmonary or cardiac disease, or diabetes mellitus, are at high risk of developing severe complications from influenza A viruses, which may include hemorrhagic bronchitis, pneumonia (primary viral or secondary bacterial), and death. Pathophysiology of influenza infection virus is transmitted through infected respiratory droplets that are aerosolised by coughing, sneezing, or talking. In influenza significant life-threatening pathological conditions that could be considered the cause of death included diffuse alveolar damage, extensive secondary pneumonia, extensive intraalveolar hemorrhage, viral pneumonitis, myocarditis and meningoencephalitis.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 8: Flu Symptoms & Treatment

Three types of flu viruses: A, B, and C are present. Type A and B cause the annual influenza epidemics that have up to 20% of the population sniffling, aching, coughing, and running high fevers. Type C also causes flu; however, type C flu symptoms are much less severe. The flu is linked to between 3,000 and 49,000 deaths and 200,000 hospitalizations each year in the United States. The seasonal flu vaccine was created to try to avert these epidemics. Ebola share some common symptoms, such as fever, headache, fatigue and aches and pains. But there are big differences, too. Influenza causes cough, sore throat and runny nose, while Ebola does not. Ebola leads to vomiting and diarrhea within three to six days, severe weakness and stomach pain, as well as unexplained bleeding and bruising. There is lots of difference between flu and flu like illness. Influenza-like illness (ILI), also known as acute respiratory infection and flu-like syndrome/symptoms, is a medical diagnosis of possible influenza or other illness causing a set of common symptoms. The causes of influenza-like illness range from benign self-limited illnesses such as gastroenteritis, rhinoviral disease, and influenza, to severe, sometimes life-threatening, diseases such as meningitis, sepsis, and leukemia.

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 9: Antivirals and Therapeutics

Antiviral drugs are prescription medicines (pills, liquid, an inhaled powder, or an intravenous solution) that fight against the flu in your body. Antiviral drugs are different from antibiotics, which fight against bacterial infections. Studies show that flu antiviral drugs work best for treatment when they are started within 2 days of getting sick. There are three FDA-approved influenza antiviral drugs recommended by CDC this season to treat influenza. The brand names for these are Tamiflu® (generic name oseltamivir), Relenza® (generic name zanamivir), and Rapivab® (generic name peramivir). Tamiflu® is available as a pill or liquid and Relenza® is a powder that is inhaled. (Relenza® is not for people with breathing problems like asthma or COPD, for example.) Rapivab® is administered intravenously by a health care provider. Viral vectors and viral vaccines more and more play an important role in current medical approaches. Higher safety demands, that is, reduction of side effects, by regulatory authorities like Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMEA), nowadays force developers as well as manufacturers to improve their production and purification processes for viral vectors and vaccines. For influenza viral vaccines, manufacturers begin to switch from egg cultivation to mammalian cell culture systems.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 10: Flu Clinical Studies & Case Reports

Flu is a contagious respiratory illness caused by influenza viruses. Most people who get influenza will recover in a few days to less than two weeks, but some people will develop complications (such as pneumonia) which are life-threatening and result in death. The high morbidity and mortality associated with both pandemic and seasonal influenza and the anticipation for future influenza pandemics puts influenza front and center in infectious disease research. Vaccine efficacy refers to studies of vaccine effects that occur under randomized, controlled conditions, where individuals are randomly assigned to either a group that is given influenza vaccine or to a second group that is not given influenza vaccine. Vaccine effectiveness is a measure of how well influenza vaccines work to protect against influenza infection and illness when they are used in routine circumstances in the community, and not specifically in a RCT. The presence of chronic medical conditions may also affect the effectiveness of influenza vaccines.

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 11: Flu Virus -Advancements in Detection & Differentiation

Influenza outbreaks and epidemics pose ongoing risks to global human public health. Recently, human infections with A/H5N1 avian influenza viruses have heightened the potential for the emergence of an influenza A virus with pandemic potential. Laboratory identification of human influenza virus infections is commonly performed using direct antigen detection, virus isolation in cell culture, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR). In recent years commercial influenza rapid diagnostic tests have become available. These are mostly antigen detection tests, which can produce results within 30 minutes. They can provide results in a clinically relevant time frame to complement the use of antiviral medications for treatment and chemoprophylaxis of influenza. Their wide availability has resulted in their increasing application to clinical situations, which may be inappropriate or where scientific data are lacking.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 

Track 12: Flu: Immunology & Genetics

Influenza is an RNA virus associated with five different viral proteins and is surrounded by a lipid membrane. Two glycoprotein molecules, known as hemagglutinin (HA) and neuraminidase (NA) on the lipid envelope and plays crucial role in the infection of the epithelial cells of the upper respiratory tract. The pathogenicity and virulence of the influenza virus is determined by several Host and Viral factors. Viruses have evolved this way in order to escape the immune systems of their hosts. The influenza virus can only replicate after invading selected living cells and growing inside them. It makes thousands of new virus particles from the cellular machinery and then goes on to infect other cells. immune mechanisms can lead to both localized as well as systemic effects. Cytokines, rapidly produced after infection by epithelial and immune cells of the respiratory mucosa, are local hormones that activate cells, especially within the immune system.

Related Conference

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2nd International Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;  UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

 

Track 13: Epidemiology and Public Health of Influenza

Public health epidemiologic investigations and surveillance are critical public health functions for identifying threats to the health of a community. In an emergency, public health surveillance is the ongoing systematic collection, analysis, interpretation, and management of public health-related data to verify a threat or incident of public health concern, and to characterize and manage it effectively through all phases of the incident. Surveillance data is used to identify and monitor the arrival of influenza, its geographic spread, intensity of activity, characteristics of those infected, as well as severity and changing trends in order to guide prevention and control recommendations.

Related Conference

2nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

 




Market Analysis Report

Importance & Scope:

Flu is an infectious disease caused by the influenza virus. Influenza is a highly contagious disease affecting almost all mammals and birds. Flu occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Illnesses can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically ill). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths.

Experts from various fields like virology, medicine, immunology, microbiology, public health planning, epidemiology, pharmacology and vaccinology all work on the flu virus. 

The infectious diseases therapeutic market in US is estimated to grow at a rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to infectious diseases globally. Current market trend shows that North America has the more global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market.

USA

CDC monitors the hospitalizations associated with laboratory-confirmed influenza virus infections Among 9,586 cases with influenza type specified, 8,497 (88.2%) were associated with influenza A virus infection, 1,046 (10.9%) with influenza B virus infection, and 43 (0.4%) were associated with mixed influenza A and influenza B virus infections. Persons aged 18–64 years accounted for 57.4% of reported hospitalizations. The cumulative incidence for all age groups for the period October 1, 2013–April 30, 2014, was 35.6 per 100,000 (Figure 3). The cumulative hospitalization rate (per 100,000 population) by age group for this period was 46.9 (for 0–4 years), 9.5 (5–17 years), 22.0 (18–49 years), 54.3 (50–64 years), and 88.1 (≥65 years).

 

Market for Flu and Emerging Infectious Diseases Research:

The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.

The Infectious disease diagnostic (IDD) market is estimated to grow at a CAGR of 7.9% to reach $18,156.2 million by 2019. Traditional diagnostic techniques such as immunodiagnostics and biochemical characterization are the largest segments of the IDD market. However, molecular diagnostic techniques, such as microarrays and isothermal nucleic acid amplification technology (INAAT), will show the fastest growth in the forecast period.

Why Las Vegas:

Emerging Infectious diseases are among the most challenging issues facing health care delivery systems around the world today. The World Health Organisation estimates that more than 17 million people die of an infectious disease each year, with many of these acquired in hospitals. Thus not only is it imperative to have rapid and efficient tests for countries in the developing world, healthcare providers in developed countries can also benefit. The situation in developed countries is probably less urgent for the tropical diseases, but it is equally important to have better rapid tests for hepatitis, HIV, tuberculosis and sexually transmissible diseases worldwide.

Fund Allotment to Flu Research:

The US government awarded five-year contracts for more than $1 billion to five drug manufacturers developing technology for speedier mass production of vaccines in the event of a pandemic from the $3.8 billion pandemic preparedness bill passed in 2005. Currently, flu vaccines are produced in specialized chicken eggs, but that technique does not allow for speedy mass vaccinations." The companies receiving the contracts were:

  • GlaxoSmithKline $274.8 million
  • Medimmune Inc $169.5 million
  • Novartis Vaccines and Diagnostics $220.5 million
  • DynPort Vaccine Company,LLC $41 million
  • Solvay Pharmaceuticals $298.6 million

The US government purchased from Sanofi Pasteur and Chiron Corporation several million doses of vaccine in case of an influenza pandemic due to H5N1 and is conducting clinical trials on them.  ABC News reported that Beginning in late 1997, the human trials have tested 30 different vaccines, all pegged to the H5N1 virus.

For H9N2 threat, NIAID contracted with Chiron Corporation to produce investigational batches of an inactivated vaccine, which will be evaluated clinically by NIAID early next year.For H5N1, Aventis-Pasteur and Chiron are both producing investigational lots of inactivated H5N1 vaccine preparations additionally, DHHS has contracted with Aventis to produce up to 2 million doses to be stockpiled for emergency use, if needed, to vaccinate health workers, researchers, and, if indicated, the public in affected areas. Development and evaluation of a combination antiviral regimen against these potential pandemic influenza strains are also now under way.

According to Global Pandemic Influenza Preparedness Markets, their size, trends and drivers, principally for the countries with health expenditures per capita exceeding $2,000. The results of this study found that since outbreaks of bird flu in 2005 and swine flu in 2009, the governments had recognized antiviral pandemic stockpiling as their preferred strategy for disease containment and mitigation. Market Research Media has found that over the past five years, government spending worldwide on Pandemic Influenza Preparedness has more than tripled from $2.2 billion in 2004 to $7 billion in 2009, at a 17% CAGR. Market Research Media forecasts that worldwide government spending on Pandemic Influenza Preparedness will continue to grow, though at more moderate rate of a 5% CAGR, reaching almost $10 billion by 2015.

The HHS announces funding of about $1 billion for clinical studies that will take place over the next few months and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.

The following companies will receive funding to produce H1N1 vaccine ingredients:

  • Novartis AG – $289 million,
  • Sanofi Aventis SA – $191 million,
  • GlaxoSmithKline PLC – $181 million,
  • Another $150 million will be directed to produce pilot lots of vaccine and to fund the clinical studies.

Reference:

  1. http://www.cdc.gov/flu/weekly/fluactivitysurv.htm
  2. http://www.cdc.gov/flu/international/program/index.htm
  3. http://www.cdc.gov/flu/weekly/fluactivitysurv.htm
  4. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  5. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  6. http://www.niaid.nih.gov/topics/flu/Pages/default.aspx
  7. http://www.idsociety.org/Research_and_Funding_Opportunities/
  8. http://www.niaid.nih.gov/news/newsreleases/2014/Pages/CEIRSnetwork.aspx
  9. https://en.wikipedia.org/wiki/Influenza_research
  10. http://www.fludb.org/brc/home.spg?decorator=influenza
  11. https://www.influenzareagentresource.org/
  12. https://www.influenzareagentresource.org/About/IRR.aspx
  13. https://www.beiresources.org/Organism/12/Influenza.aspx
  14. http://www.atcc.org/en/About/Grants_and_Contracts/Influenza_Reagent_Resource.aspx
  15. http://www.influenzavir.com/cms/

 





Past Conference Report

Flu-2016

Conference series LLC hosted the “2nd International Conference on Flu” during October 31-November 02, 2016 at DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, USA with the theme Scientific Milestones in Understanding and Preventing Flu” where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.

Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Virologists, scientists, researchers, students and leaders in Flu Research, who made this event successful.

The Conference was carried out through various informative and cutting edge sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

  • Flu Vaccines: Current and Novel Approach
  • Pathology of Influenza Virus Infections
  • Flu Symptoms & Treatment
  • Antivirals and Therapeutics
  • Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups
  • Flu Virus -Advancements in Detection & Differentiation
  • Flu: Immunology & Genetics
  • Flu Clinical Studies & Case Reports
  • Epidemiology and Public Health of Influenza
  • Surveillance Issues and Burden of Disease

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

  • Donald P Francis, Global Solutions for Infectious Diseases, USA
  • Ananda M Chakrabarty, University of Illinois College of Medicine, USA
  • Anthony S Gilbert, hVIVO, UK
  • Palayakotai Raghavan, Nanorx Inc, USA
  • Manon M J Cox, Protein Sciences, USA
  • Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA
  • Sunil K Lal, Monash University, Malaysia

All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Jun Wang, University of Arizona, USA and Sunil K Lal, Monash University, Malaysia for his remarkable contribution towards smooth functioning at Flu-2016 Conference.

Conference Sessions Chairs:      

  • Donald P Francis, Global Solutions for Infectious Diseases, USA
  • Palayakotai Raghavan, Nanorx Inc, USA
  • Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA

Conference Series LLC offers its heartfelt appreciation to Societies and Organizations includes Allied AcademiesAndrew John Publishing Inc., New York Private Equity Forums and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series LLC in supporting and making the conference a never before one.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph Flu-2016, Conference Series LLC is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, "3rd International Conference on Flu & Emerging Infectious Diseases" to be held during Oct 30-Nov 01, 2017 at Las Vegas, USA.

Let us meet again @ Flu-2017


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 30-November 1, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations